Zydus Lifesciences Extends API Business Acquisition Timeline
Filing Summary
Zydus Lifesciences Ltd has announced an extension in the timeline for acquiring the API business of Sterling Biotech Limited. Initially expected to close by December 31, 2024, the transaction’s completion date was first extended to December 31, 2025. Due to pending conditions precedent, the closing date is now further extended to June 30, 2026. This update follows the Business Transfer Agreement executed between the two companies. Zydus Lifesciences continues to work towards finalizing the acquisition as per the revised timeline.
On December 24, 2025, Zydus Lifesciences Ltd provided an update regarding its acquisition of the API business from Sterling Biotech Limited (SBL). The company had previously entered into a Business Transfer Agreement (BTA) for this acquisition, with an initial completion target of December 31, 2024.
In a subsequent update on September 30, 2025, Zydus Lifesciences informed that both parties had mutually agreed to extend the closing date to December 31, 2025. However, as certain conditions precedent outlined in the BTA remain incomplete, the closing date has now been further extended to June 30, 2026. This extension was formalized through a letter executed by both companies.
Zydus Lifesciences is focused on expanding its capabilities in the pharmaceutical sector, particularly in the area of active pharmaceutical ingredients (API). The company continues to pursue strategic acquisitions to enhance its product offerings and market presence.